Zusammenfassung
Hintergrund
Homogene Pigmentierung lässt sich durch Strukturverwandte des α-MSH erzielen. Zu den kosmetisch störenden Hyperpigmentierungen zählen vor allem die der Gesichtsregion.
Fragestellung
Während Afamelatonid als „orphan drug“ für die erythropoetische Protoporphyrie zugelassen ist, sind weitere Strukturverwandte über Internetquellen zur Bräunung zu beziehen. Präventiv und therapeutisch zu beeinflussen sind vor allem die postentzündliche Hyperpigmentierung, Melasma und Lentigines.
Methoden
Einzelfallberichte zur Aktivierung dysplastischer Nävi unter Melanotan I liegen vor. Das Woodlicht hilft, die Tiefe der Hyperpigmentierung einzuschätzen. Da keine Leitlinien vorliegen, wird die Lehrmeinung anhand von Studien dargestellt.
Ergebnisse
Melanotan führt zur Aktivierung dysplastischer Nävi. Der Goldstandard in der Behandlung von Hyperpigmentierungen ist die Dreierkombination aus Hydrochinon, Tretinoin und einem topischen Steroid, allerdings oft mit dem Nebeneffekt der Irritation und gelegentlich Ochronose. Tyrosinaseinhibitoren, schälende Substanzen und Pflanzeninhaltsstoffe konnten diese Wirkungsstärke nicht erreichen, werden jedoch besser toleriert.
Schlussfolgerungen
Melanotan und Bleichcremes, die evtl. Quecksilber enthalten, aus dem Internet sind gesundheitsschädlich. Hyperpigmentierungen erfordern Kombinationstherapien aus Hemmung der Aktivität der Melanozyten und der Melaninsynthese, Entfernen des Melanins, Zerstörung der Melaningranula und Lichtschutz. Besonders bei Fitzpatrick-Hauttyp IV–VI können Kryotherapie und Laseranwendungen zu posttherapeutischer erneuter Hyperpigmentierung führen.
Abstract
Background
Homogenous pigmentation can be induced by α-melanocyte-stimulating hormone (MSH) homologues. Cosmetically inacceptable pigmentation is mostly located on the face.
Objectives
Although afamelatonide is a prescription drug for the orphan disease erthropoetic protoporphyria, structurally related α-MSH derivatives are available via the internet. Preventive and therapeutical options are necessary for postinflammatory hyperpigmentation, melasma, and lentigines.
Methods
Case reports address activation of dysplastic naevi by melanotan I. Wood's lamp is of some use in analyzing the level of hyperpigmentation. However, no guidelines have been established; thus, a summary of current studies is presented.
Results
Melanotan I leads to the activation of dysplastic nevi. The gold standard for hyperpigmentation is triple therapy with hydrochinon, tretinoin, and steroids, which can cause irritation and lead to ochronosis in some individuals. Tyrosinase inhibitors, substances that increase the cell turnover, and plant derivatives are less efficient but more tolerable.
Conclusions
Melanotan I and bleaching creams, which may possibly contain mercury, are dangerous. Hyperpigmentation is best treated using a combination therapy that inhibits melanocyte activity and melanin synthesis, removes melanin, destroys melanin granules, and includes UV protection. Especially in Fitzpatrick skin types IV–VI, cryotherapy and laser are not the first line treatment options due to renewed posttreatment hyperpigmentation.
Literatur
Anderson RR, Parrish JA (1983) Selective photothermolysis: precise microsurgery by selective absorption of pulsed radation. Science 220(4596):524–527
Bayerl C (2005) Topical treatment of skin aging. Hautarzt 56:328, 330–334, 336–339
Böhm M, Luger TA (2010) Alpha-melanocyte-stimulatin hormone. From bench to bedside. Hautarzt 61:497–504
Chance AW (2014) Treatment of unwanted pigment. Facial Plast Surg 30:16–25
Cheyasak N, Manuskiatti W, Maneeprasopchoke P et al (2015) Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional C02 laser resurfacing in Asians. Acta Derm Venereol 95:201–205
Coulsen P, Colver G, Helbling I (2009) Eruptive naevi following melanotan injection. Br J Dermatol 161:707–708
Elsner P, Fluhr JW, Gehring W et al (2011) Anti-aging data and support claims – consensus statement. J Dtsch Dermatol Ges 3:S1–S32
Fisk W, Agbai O, Lev-Tov HA, Sivamani RK (2014) The use of botanically derived agents for hyperpigmentation: a systematic review. J Am Acad Dermatol 70:352–365
Fistarol SK, Itin PH (2010) Disorders of pigmentation. J Dtsch Dermatol Ges 8:187–202
Hakozaki T, Minwalla L, Zhuang J et al (2002) The effect of niacinamide on reducing cutaneaous pigmentation and suppression of melanosome transfer. Br J Dermatol 147:20–31
Hamann CR, Boonchai W, Wen L et al. (2014) Spectrometric analysis of mercury content in 549 skin-lightening products: is mercury toxicity a hidden global health hazard? J Am Acad Dermatol 70:281–287
Held B, Bayerl C (2008) Chronische Quecksilberintoxikation bei Kindern aus zwei Familien durch kosmetische Anwendung einer Bleichcreme seitens der Mütter. Akt Dermatol 34:274–278
Juhlin L, Alkemade H (1999) Erythrosis pigmentosa mediofacialis (Brocq) and erythromelanosis follicularis faciei et colli in the same patient. Acta Derm Venerol 79:65–66
Kato H, Araki J, Eto H (2011) A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser. Dermatol Surg 37:605–610
Kerscher M (2012) Antifaltencremes – Was hilft wirklich? J Aesthet Chir 5:74–82
Kim S, Cho KH (2010) Treatment of procedure-related postinflammatory hyperpigmentation using 1064 nm Q-switched Nd-YAG laser with low fluence in Asian patients: report of five cases. J Cosmet Dermatol 9:302–306
Kolbe L, Mann T, Gerwat W et al (2013) 4-n-buylresorcinol, a highly effective tyrosinase inhbitor fort he topical treatment of hyperpigmentation. J Eur Acad Dermatol Venereol 27:S19–S23
Kondo T, Hearing VJ (2011) Update on the regulation of mammalian melanocyte function and skin pigmentation. Expert Rev Dermatol 6:97–108
Lee JH, Park JG (2006) Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preleminary clinical trial. Dermatol Surg 32:626–631
Mahajan R, Kanwar AJ, Parsad D et al (2015) Glycolic acid peels/azelaic acid 20 % cream combination and low potency triple combination lead to similar reduction in melasma severityin in ethnic skin: results of a randomized controlled study. Indian J Dermatol 60:147–152
Na SY, Cho S, Lee JH (2012) Intense pulsed light and low-fluence Q-switched Nd:YAG laser treatment in melasma patients. Ann Dermatol 24:267–273
Nenoff P, Müller H, Schulze J et al (2015) Diffus grauschwarze Hyerpigmentierung der Gesichtshaut bei einer 59-jährigen Patientin. Hautarzt 66:214–217
Nicolaidou E, Katsambas A (2014) Pigmentation disorders: hyperpigmentation and hypopigmentation. Clin Dermatol 32:66–72
Nieuweboer-Krobotova L (2013) Hyperpigmentation: types, diagnostics and targeted treatment options. J Eur Acad Dermatol Venereol 27:S2–S4
Ong S, Bowling I (2012) Melanotan-associated melanoma in situ. Australas J Dermatol 53:301–302
Passeron T (2013) Melasma pathogenesis and influencing factors – an overview of the latest research. J Eur Acad Dermatol Venereol 27:S5–S6
Quillen EE, Shriver M (2011) Unpacking human evolution to find genetic determinants of human skin pigmentation. J Invest Dermatol 131:E5–E7
Rajaratnam R, Halpern J, Salim A, Emmett C (2010) Interventions for melasma. Cochrane Database Syst Rev 7:CD003583. doi:10.1002/14651858
Ramien MI, Ondrejchak S (2014) Quality of life in pediatric patients before and after cosmetic camouflage of visible skin conditions. J Am Acad Dermatol 71:935–940
Reid C, Fitzgerald T, Fabre A, Kirby B (2103) Atypical melanocytic naevi following melanotan injection. Ir Med J 106:148–149
Rivas S, Pandya AG (2013) Treatment of melasma with topical agents, peels and lasers: an evidence-based review. Am J Clin Dermatol 14:359–376
Schulze F, Erdmann H, Hardkop LH et al (2104) Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. Eur J Dermatol 24:107–109
Shankar K, Godse K, Aurangabadkar S et al (2014) Evidence-based treatment for melasma: expert opinion and review. Dermatol Ther (Heidelb) 4:165–186
Sheth V, Pandya AG (2011) Melasma: a comprehensive update. J Am Acad Dermatol 65:699–714
Stern RS, Dower JS, Levin JA, Arndt KA (1994) Laser therapy versus cryotherapy of lentigines: a comparative trial. J Am Acad Dermatol 30:985–987
Viekötter A, Schikowski T, Ranft E et al (2010) Airborne particle exposure and extrinsic skin aging. J Invest Dermatol 130:2719–2726
Volks N, Fölster-Holst R (2014) Erythromelanosis follicularis faciei – variante der Keratosis pilaris? J Dtsch Dermatol Ges 13:51–54
Worret W-I, Gehring W (2008) Kosmetische Dermatologie, 2. Aufl. Springer, Heidelberg
Wu S, Shi H, Wu H et al (2012) Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg 36:964–970
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
C. Bayerl gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Bayerl, C. Unerwünschte und erwünschte Pigmentierung. Hautarzt 66, 757–763 (2015). https://doi.org/10.1007/s00105-015-3671-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-015-3671-4